(Sharecast News) - Hutchmed China announced on Thursday that it was set to receive a $20m milestone payment from its partner Takeda, after sales of 'Fruzaqla', or fruquintinib, surpassed $200m.

The AIM-traded firm said the drug, used to treat metastatic colorectal cancer (CRC), generated $203m in net sales in the...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE